Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology-focused company, announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The event will feature an on-demand presentation starting May 24 at 7:00 AM EDT, along with one-on-one meetings. Sol-Gel specializes in developing topical drugs, including TWYNEO® for acne treatment and EPSOLAY for rosacea, both licensed to Galderma. The company is also advancing early-stage drug candidates for various dermatological diseases.

NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that the Company will present at the upcoming H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

Event:	H.C. Wainwright Global Investment Conference
Date:	May 23-26 2022
Format:	On-demand presentation and 1:1 meetings
Time:	Presentation available on-demand beginning Tuesday, May 24th at 7:00 am Eastern Daylight Time
Webcast:	Link

About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing or partnering branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leveraged its proprietary microencapsulation technology platform for TWYNEO^®, which is approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to Galderma for U.S. commercialization.

The Company’s pipeline also includes early-stage topical drug candidates SGT-210, SGT-310 and SGT-510 under investigation for the treatment of plaque psoriasis and other dermatologic indications.

For further information, please contact:

Investors:

Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1 917 734 7387

Sol-Gel Technologies

Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com

FAQ

When is the H.C. Wainwright Global Investment Conference for Sol-Gel Technologies (SLGL)?

The H.C. Wainwright Global Investment Conference is scheduled for May 23-26, 2022.

What will Sol-Gel Technologies present at the conference?

Sol-Gel Technologies will present an on-demand presentation and hold one-on-one meetings at the conference.

When will the on-demand presentation from Sol-Gel Technologies (SLGL) be available?

The on-demand presentation will be available starting May 24, 2022, at 7:00 AM Eastern Daylight Time.

What is the focus area of Sol-Gel Technologies (SLGL)?

Sol-Gel Technologies specializes in developing branded and generic topical drugs for treating skin diseases.

What products does Sol-Gel Technologies (SLGL) currently commercialize?

Sol-Gel Technologies currently commercializes TWYNEO® for acne and EPSOLAY for rosacea.